A German team has reported the treatment with autologous anti-CD19 CAR-T cells of two women with both autoimmune myasthenia and Lambert-Eaton syndrome who had failed to respond to multiple immunotherapies.
The two patients, who were wheelchair-dependent before the transplant, regained full mobility, enabling them to cycle and go hiking in the mountains, in particular, within two months of receiving CAR T cells. At the same time, clinical recovery was accompanied by a profound depletion of B cells and a normalisation of anti-RACh and anti-VGCC antibodies. One patient was stable at 4 months and the other at 6 months post-infusion.
These CAR-T cells (KYV-101), developed by Kyverna therapeutics, will be studies in a clinical trial in the United States in refractory generalised myasthenia gravis.
